VivoSeq
Infectious Disease

Clostridium Difficile

0

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Clostridium Difficile is an early-stage landscape with 0 programs across 4 companies. The most active players are Pfizer, Sanofi, Summit Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

72/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalS

Summit Therapeutics

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

26

clinical trials

Completed18 · 69%
Terminated4 · 15%
Withdrawn3 · 12%
Unknown status1 · 4%

Clinical Trials

Trial Activity

26 trials

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years
Completed·Pfizer logoPfizer·Phase 2·NCT02561195·300 enrolled
Clostridium Difficile Vaccine Efficacy Trial
Completed·Pfizer logoPfizer·Phase 3·NCT03090191·17,535 enrolled
Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults
Completed·Pfizer logoPfizer·Phase 1·NCT02725437·100 enrolled
Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
Completed·VValneva Austria GmbH·Phase 2·NCT02316470·500 enrolled
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
Completed·Pfizer logoPfizer·Phase 2·NCT02117570·185 enrolled
Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
Completed·Pfizer logoPfizer·Phase 3·NCT03918629·1,994 enrolled
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
Completed·Pfizer logoPfizer·Phase 3·NCT03579459·1,317 enrolled
Chlorhexidine Bathing Effect on Clostridium Difficile Rates
Completed·—·Phase 2·NCT02502682·167 enrolled
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
Completed·Pfizer logoPfizer·Phase 1·NCT01706367·192 enrolled
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Completed·SSummit Therapeutics·Phase 2·NCT02092935·100 enrolled
Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers
Completed·Sanofi logoSanofi·Phase 1·NCT00127803·50 enrolled
Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea
Completed·National Health Service, United Kingdom·Phase 2/3·NCT00973908·231 enrolled
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
Completed·Pfizer logoPfizer·Phase 1·NCT02052726·184 enrolled
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Completed·Sanofi logoSanofi·Phase 2·NCT01230957·650 enrolled
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan
Completed·Sanofi logoSanofi·Phase 1/2·NCT01896830·102 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)